TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker)(TRAF1/3298) , Biotin conjugate , 0.1mg / mL

This MAb recognizes a protein of 52 kDa , which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically , histopathologically , immunopathologically and genetically , they differ considerably in their prognosis. In particular , common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However , both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously , whereas those of cALCL persist and may progress and spread. Moreover , LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach , in contrast to patients with cALCL. Besides , LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1) , a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression , tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations. Primary antibodies are available purified , or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets , because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.